Berlin - Captain T Cell GmbH, a biotechnology company developing next-generation T cells against solid tumors, has successfully completed a seed financing round with a volume of EUR 8.5 million. Several experienced life science investors participated in the financing round, in particular Brandenburg Kapital GmbH, i&i Biotech Fund I SCSp and the Austrian HIL-Invent Ges.m.b.H. Captain T Cell aims to use the newly raised funds to advance its program for the off-the-shelf treatment of solid tumors towards the clinic. Captain T Cell is a spin-off from one of Europe's leading biomedical research institutions, the Max Delbrück Center in Berlin.
A CMS team head by partner Dr Jörg Zätzsch advised Brandenburg Kapital on all legal aspects of this investment in Captain T Cell. Brandenburg Kapital once again relies on the advice of the CMS team headed by Dr Jörg Zätzsch. For example, most recently on the investment in Seqstant, a software provider for the live analysis of pathogens. Investors as well as start-ups and company founders regularly rely on the advice of CMS' venture capital teams.
Brandenburg Kapital GmbH is a subsidiary of the Investitionsbank des Landes Brandenburg (ILB). As the venture capital arm of the ILB, it has been supporting Brandenburg companies since 1993 by acquiring equity and equity-like investments.
Press Contact
presse@cms-hs.com
